Skip to main content
SpringerLink
Log in

Furmonertinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Furmonertinib mesylate (hereafter furmonertinib) [Ivesa®] is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Allist Pharmaceuticals for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In March 2021, furmonertinib received its first approval in China for the treatment of patients with locally advanced or metastatic NSCLC with confirmed EGFR T790M mutation whose disease has progressed during or after EGFR TKI therapy. Furmonertinib (as monotherapy and/or combination therapy) continues to be assessed in phase I/II and phase III trials for NSCLC with EGFR mutation in China, and its clinical development is also underway/planned in China and elsewhere for NSCLC with various EGFR mutations. This article summarizes the milestones in the development of furmonertinib leading to this first approval for EGFR T790M-positive NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee SM. Is EGFR expression important in non-small cell lung cancer? Thorax. 2006;61(2):98–9.

    Article  CAS  Google Scholar 

  2. Pacini L, Jenks AD, Vyse S, et al. Tackling drug resistance in EGFR exon 20 insertion mutant lung cancer. Pharmgenomics Pers Med. 2021;14:301–17.

    PubMed  PubMed Central  Google Scholar 

  3. Khaddour K, Jonna S, Deneka A, et al. Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: current and emerging therapies. Cancers (Basel). 2021;13(13):3164. https://doi.org/10.3390/cancers13133164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Le T, Gerber DE. Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers (Basel). 2019;11(3):366. https://doi.org/10.3390/cancers11030366.

    Article  CAS  PubMed Central  Google Scholar 

  5. National Medical Products Administration. The State Food and Drug Administration has conditionally approved the listing of vometinib mesylate tablets. 2021. https://www.nmpa.gov.cn. Accessed 3 Aug 2021.

  6. Shanghai Allist Pharmaceutical Technology Co Ltd. Furmonertinib mesilate: Chinese prescribing information. Shanghai: Shanghai Allist Pharmaceutical Technology Co Ltd; 2021.

  7. Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs. 2018. https://www.engage.hoganlovells.com/knowledgeservices/news/the-china-food-and-drug-administration-pushes-forward-on-conditional-approval-and-compassionate-use-of-new-drugs. Accessed 3 Aug 2021.

  8. ArriVent Biopharma. ArriVent Biopharma launches with up to $150M in Series A financing and strategic licensing agreement for clinical-stage oncology asset [media release]. 30 June 2021. https://www.arrivent.com.

  9. Liu X, Li W, Zhang Y, et al. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2019;176: 112735. https://doi.org/10.1016/j.jpba.2019.06.032.

    Article  CAS  PubMed  Google Scholar 

  10. Zhu S, Deng J, Tang Q, et al. A randomized, open, single-centre, crossed study of the effect of food on the pharmacokinetics of one oral dose of alflutinib mesylate tablets (AST2818) in healthy male subjects. Iranian J Pharm Res. 2020;19(3):24–33.

    CAS  Google Scholar 

  11. Liu XY, Guo ZT, Chen ZD, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin. 2020;41(10):1366–76.

    Article  CAS  Google Scholar 

  12. Meng J, Zhang H, Bao JJ, et al. Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans. Acta Pharmacol Sin. 2021. https://doi.org/10.1038/s41401-021-00667-8.

    Article  PubMed  Google Scholar 

  13. Heng J, Tang Q, Chen X, et al. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. Eur J Pharm Sci. 2021;162: 105815. https://doi.org/10.1016/j.ejps.2021.105815.

    Article  CAS  PubMed  Google Scholar 

  14. Zhu YT, Zhang YF, Jiang JF, et al. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers. Invest New Drugs. 2021;39(4):1011–8.

    Article  CAS  Google Scholar 

  15. Wu YL, Xue YR, Guo ZT, et al. Furmonertinib (alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes. Acta Pharmacol Sin. 2021. https://doi.org/10.1038/s41401-021-00692-7.

    Article  PubMed  Google Scholar 

  16. Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021;26:1–11.

    Google Scholar 

  17. Shi Y, Zhang S, Hu X, et al. Safety, clinical activity and pharmacokinetics of alflutinib (AST2818) in advanced NSCLC patients with EGFR T790M mutation. J Thorac Oncol. 2020;15(6):1015–26.

    Article  CAS  Google Scholar 

  18. Shi Y, Hu X, Liao W, et al. CNS efficacy of AST2818 in patients with T790M-positive advanced NSCLC: data from a phase I-II dose-expansion study [abstract no. P76.65]. J Thoracic Oncol. 2021;16(3 Suppl):S616.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 502 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Furmonertinib: First Approval. Drugs 81, 1775–1780 (2021). https://doi.org/10.1007/s40265-021-01588-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01588-w

Search

Navigation